February 2, 2010 (FinancialWire) — Resverlogix Corp. (TSX: RVX) (OTC: RVXCF) said that its board of directors has elected Arthur J. Higgins, the CEO of Bayer HealthCare and chairman of the Bayer HealthCare Executive Committee, to the Resverlogix board effective February 1.

Higgins joined Bayer in 2004 as chairman of the Bayer HealthCare Executive Committee and in 2006 was named chairman of the board of Management of Bayer HealthCare.

Higgins started his career in 1978 in England with Bristol-Myers.

Canada-based Resverlogix is a biotechnology company engaged in the development of novel therapies for various global medical markets. The company’s primary focus is the NexVas PR program, which is meant to develop novel small molecules that enhance ApoA-I. These therapies are designed to address atherosclerosis and other diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer’s disease, Peripheral Artery Disease and other vascular disorders.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.